Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Yu Zhou, PhD

Title(s)Professor, Anesthesia
SchoolSchool of Medicine
Address2540 23rd Street, #5709
San Francisco CA 94110
ORCID ORCID Icon0000-0002-5130-4042 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    UC San Francisco, 1001 Potrero Ave, San Francisco, CA 94110Post-doc03/2004Antibody Engineering
    Peking University, Beijing, PRCPh.D.10/2000Protein Engineering
    Peking University, Beijing, PRCM.S.7/1991Molecular Biology
    Peking University, Beijing, PRCB.S.7/1988Biochemistry
    Collapse awards and honors
    UCSF, BOP2006Best in Show Poster
    UCSF, BOP2013Best Therapeutics & Clinic Trials Poster Award

    Collapse Overview 
    Collapse overview
    My research interests are in the areas of protein function-structure relationship, protein-protein interactions, and the intervention of protein interactions by antibodies. Current research focuses are recombinant antibody library design, mAb discovery and engineering, immuno-diagnostics and therapeutics. I have worked on projects that include 1) the discovery and engineering of internalizing mAbs targeting basal subtype breast cancer associated membrane proteins for drug delivery, 2) the discovery and engineering of mAbs against serum biomarkers for pancreatic cancer early diagnosis, 3) engineering of antibody Fc to enhance antibody dependent cellular cytotoxicity (ADCC) and pharmacokinetics, 4) the development of host-targeted broad-spectrum anti-viral therapy, 5) the establishment of high-throughput antibody discovery platform, 6) development of therapeutic mAbs to immune-oncological targets, 7) design and construction of recombinant antibody libraries, and 8) impact of germline sequences to antibody developability. The high-throughput antibody discovery is powerful for generating data of antibody-antigen interactions, which can help uncover protein-protein interactions and the de novo design of antibodies. The phage display and yeast display platform allowed identifying mAbs with high affinity and cross-reactivity, can be applied to all immune-oncological targets.

    Collapse Research 
    Collapse research activities and funding
    Development of monoclonal antibody ultrasensitive assays for diagnosis of infant botulism
    California Department of Public Health 24-10011Jul 1, 2024 - Jun 30, 2027
    Role: Co-Investigator
    Description: The overall goal of this work continues to be for the UCSF Marks Laboratory (Contractor) to generate and improve monoclonal antibodies (mAbs) that will be used in the ultrasensitive assays for several botulinum neurotoxins (BoNTs) that the California Department of Public Health (CDPH)/Infant Botulism Treatment and Prevention Program (IBTPP) is developing.
    A novel bispecific antibody to disrupt the B cell-T cell axis in multiple sclerosis and other autoimmune disease
    Weill Institute of Neurosciences Mar 1, 2024 - Jun 30, 2026
    Role: PI
    Description: To develop cis-targeting mAbs for CD3 and CD20 double positive T cells causing autoimmune deseases Engineer bispecific antibody to CD3e and CD20 for cis-targeting of CD3 and CD20 double positive T cells
    Development of monoclonal antibody-based ultrasensitive assays for diagnosis of infant botulism
    California Department of Public Health A137212Jul 1, 2021 - Jun 30, 2024
    Role: Co-Investigator
    Description: The goal is to engineer human mAbs to botulinum neurotoxins (BoNT) with super high specificity and affinity. The identified human mAbs will be developed for ultrasensitive detection of BoNTs and diagnosis.
    Human mAbs to cell type specific antigens
    Silvercreek Pharmaceuticals A137160Jul 1, 2021 - Jun 30, 2023
    Role: Principal Investigator
    Description: The goal is to screen both human naïve and human-emulating single chain Fv libraries to identify human mAbs to cell type specific antigens. The identified human mAbs will be further developed for targeted regenerative therapeutics.
    Internalizing and cross-reactive human mAbs to tumor associate antigen
    ImmunoGen, Inc. A131104Apr 1, 2018 - Mar 31, 2019
    Role: Principal Investigator
    Cross reactive human mAbs to tumor associated antigens
    Merrimack Pharmaceuticals, Inc. A128580Aug 1, 2016 - Jul 31, 2018
    Role: Principal Investigator
    Description: Lead the development and application of display antibody libraries for isolation of human monoclonal antibodies to various immune-oncology targets, direct the research, construct and supervise the overall research plan
    The antibody technology research center: renewable antibodies to biomedical relevant antigens
    NIH/NCI 1P41CA196276-01Nov 1, 2014 - Oct 31, 2019
    Role: Co-Investigator
    Description: Lead the Project 1 to construct nature-inspired recombinant antibody libraries, develop high-throughput antibody selection platform, identify target specific antibodies, and study antibody structure-function relationship.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Multicolor fluorescence activated cell sorting to generate humanized monoclonal antibody binding seven subtypes of BoNT/F. PLoS One. 2022; 17(9):e0273512. Fan Y, Sun Z, Conrad F, Wen W, Zhao L, Lou J, Zhou Y, Farr-Jones S, Marks JD. PMID: 36048906; PMCID: PMC9436041.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    2. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance. Front Immunol. 2021; 12:686439. Muller YD, Ferreira LMR, Ronin E, Ho P, Nguyen V, Faleo G, Zhou Y, Lee K, Leung KK, Skartsis N, Kaul AM, Mulder A, Claas FHJ, Wells JA, Bluestone JA, Tang Q. PMID: 34616392; PMCID: PMC8488356.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimalsCells
    3. Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity. Sci Transl Med. 2019 10 02; 11(512). Tam EM, Fulton RB, Sampson JF, Muda M, Camblin A, Richards J, Koshkaryev A, Tang J, Kurella V, Jiao Y, Xu L, Zhang K, Kohli N, Luus L, Hutto E, Kumar S, Lulo J, Paragas V, Wong C, Suchy J, Grabow S, Dugast AS, Zhang H, Depis F, Feau S, Jakubowski A, Qiao W, Craig G, Razlog M, Qiu J, Zhou Y, Marks JD, Croft M, Drummond DC, Raue A. PMID: 31578241.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCells
    4. Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. Nat Biomed Eng. 2019 04; 3(4):264-280. Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, Dumont N, Lugovskoy AA, Schihl SA, Wilton JH, Geddie ML, Suchy J, Grabow S, Kohli N, Reynolds CP, Blaydes R, Zhou Y, Sawyer AJ, Marks JD, Drummond DC. PMID: 30952988.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    5. Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel. 2018 01 01; 31(1):17-28. Zhou Y, Zou H, Yau C, Zhao L, Hall SC, Drummond DC, Farr-Jones S, Park JW, Benz CC, Marks JD. PMID: 29301020; PMCID: PMC6283401.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    6. Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5. Mol Cancer Ther. 2015 Nov; 14(11):2595-605. Le Gall M, Crépin R, Neiveyans M, Auclair C, Fan Y, Zhou Y, Marks JD, Pèlegrin A, Poul MA. PMID: 26358753; PMCID: PMC6013065.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    7. Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation. Leukemia. 2016 Mar; 30(3):692-700. Seldon TA, Pryor R, Palkova A, Jones ML, Verma ND, Findova M, Braet K, Sheng Y, Fan Y, Zhou EY, Marks JD, Munro T, Mahler SM, Barnard RT, Fromm PD, Silveira PA, Elgundi Z, Ju X, Clark GJ, Bradstock KF, Munster DJ, Hart DN. PMID: 26286117.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    8. A fully human scFv phage display library for rapid antibody fragment reformatting. Protein Eng Des Sel. 2015 Oct; 28(10):307-16. Li K, Zettlitz KA, Lipianskaya J, Zhou Y, Marks JD, Mallick P, Reiter RE, Wu AM. PMID: 25991864; PMCID: PMC4607741.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    9. High throughput identification of monoclonal antibodies to membrane bound and secreted proteins using yeast and phage display. PLoS One. 2014; 9(10):e111339. Zhao L, Qu L, Zhou J, Sun Z, Zou H, Chen YY, Marks JD, Zhou Y. PMID: 25353955; PMCID: PMC4213037.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    10. Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther. 2014 Nov; 13(11):2607-17. Li K, Tavaré R, Zettlitz KA, Mumenthaler SM, Mallick P, Zhou Y, Marks JD, Wu AM. PMID: 25143449; PMCID: PMC4221648.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimals
    11. Identifying blood-brain-barrier selective single-chain antibody fragments. Biotechnol J. 2014 May; 9(5):664-74. Jones AR, Stutz CC, Zhou Y, Marks JD, Shusta EV. PMID: 24644233; PMCID: PMC4073886.
      View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCells
    12. N-Terminal labeling of filamentous phage to create cancer marker imaging agents. ACS Nano. 2012 Aug 28; 6(8):6675-80. Carrico ZM, Farkas ME, Zhou Y, Hsiao SC, Marks JD, Chokhawala H, Clark DS, Francis MB. PMID: 22830952; PMCID: PMC3435507.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    13. Selection and characterization of cell binding and internalizing phage antibodies. Arch Biochem Biophys. 2012 Oct 15; 526(2):107-13. Zhou Y, Zhao L, Marks JD. PMID: 22627065; PMCID: PMC4209712.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    14. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies. Mol Cancer Ther. 2012 Jul; 11(7):1467-76. Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD. PMID: 22564724; PMCID: PMC4209485.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    15. Discovery of internalizing antibodies to tumor antigens from phage libraries. Methods Enzymol. 2012; 502:43-66. Zhou Y, Marks JD. PMID: 22208981; PMCID: PMC4180867.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    16. Building and characterizing antibody-targeted lipidic nanotherapeutics. Methods Enzymol. 2012; 502:139-66. Kirpotin DB, Noble CO, Hayes ME, Huang Z, Kornaga T, Zhou Y, Nielsen UB, Marks JD, Drummond DC. PMID: 22208985.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    17. Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens. J Mol Biol. 2010 Nov 19; 404(1):88-99. Zhou Y, Zou H, Zhang S, Marks JD. PMID: 20851130; PMCID: PMC4195448.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    18. TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS. Am J Transl Res. 2010 Jul 20; 2(4):368-80. Diaz L, Mao H, Zhou Y, Kohli M, Cassella J, Santos D, Fesseha Z, Weng K, Chen H, Bamba D, Marks JD, Goldblatt M, Kinch M. PMID: 20733947; PMCID: PMC2923861.
      View in: PubMed   Mentions: 2  
    19. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging. 2010 Aug; 37(8):1529-38. Lepin EJ, Leyton JV, Zhou Y, Olafsen T, Salazar FB, McCabe KE, Hahm S, Marks JD, Reiter RE, Wu AM. PMID: 20354850; PMCID: PMC2903645.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimalsCells
    20. Identification of target and function specific antibodies for effective drug delivery. Methods Mol Biol. 2009; 525:145-60, xv. Zhou Y, Marks JD. PMID: 19252832.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    21. Development of human single-chain antibodies against SARS-associated coronavirus. Intervirology. 2008; 51(3):173-81. Leung KM, Feng DX, Lou J, Zhou Y, Fung KP, Waye MM, Tsui SK, Chan PK, Marks JD, Pang SF, Kan YW. PMID: 18724064; PMCID: PMC7179547.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    22. Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Mol Immunol. 2007 Jul; 44(15):3777-88. Goenaga AL, Zhou Y, Legay C, Bougherara H, Huang L, Liu B, Drummond DC, Kirpotin DB, Auclair C, Marks JD, Poul MA. PMID: 17498801; PMCID: PMC2739904.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    23. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol. 2007 Aug 24; 371(4):934-47. Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks JD. PMID: 17602702; PMCID: PMC4198021.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCells
    24. Isolation of scFvs to in vitro produced extracellular domains of EGFR family members. Cancer Biother Radiopharm. 2005 Dec; 20(6):603-13. Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks JD. PMID: 16398612.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    Yu's Networks
    Concepts (164)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (15)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-16-gff1bd585 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.